{"transactions":[{"id":4619869,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":38283,"kind":"person","name":"Chan Phillip P.","position":1,"cik":"0001442786","reported_name":"Chan Phillip P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-16T21:30:30.000Z","date":"2026-09-15","kind":"purchase","planned":false,"acquired":true,"shares":3774,"price":6,"value":22644.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (i) the following restricted stock units (\"RSUs\") that will be settled into shares of Common Stock upon vesting upon a \"Change In Control\" of CytoSorbents Corporation (the \"Issuer\") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (a) 515 RSUs granted on March 15, 2018, (b) 935 RSUs granted on February 24, 2017, (c) 2,850 RSUs granted on June 7, 2016 and (d) 6,500 RSUs granted on April 8, 2015;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (ii) 2,640 RSUs of 5,280 granted on August 8, 2025, which vest in equal parts at the first and second year anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and (iii) 83,782 shares of Common Stock owned by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026."}],"balance_after":100996,"source":{"system":"sec-edgar","filing":"0001104659-26-108326","document":"tm2625479-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442786/000110465926108326/tm2625479-3_4seq1.xml","form_type":"4"}},{"id":4619185,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76776,"kind":"person","name":"Capponi Vincent","position":1,"cik":"0001368151","reported_name":"Capponi Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2026-09-16T20:05:30.000Z","date":"2026-09-14","kind":"purchase","planned":false,"acquired":true,"shares":273,"price":5.9,"value":1610.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (i) the following RSUs that will be settled into Common Stock upon vesting upon a \"Change In Control\" of CytoSorbents Corporation (the \"Issuer\") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (a) 505 RSUs granted on March 15, 2018, (b) 895 RSUs granted on February 24, 2017, (c) 2,700 RSUs granted on June 7, 2016 and (d) 6,250 RSUs granted on April 8, 2015;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (ii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 4,455 RSUs granted on August 8, 2025 and of which 2,228 remain unvested as of the date hereof; and"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iii) 25,736 shares of Common Stock owned by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026."}],"balance_after":40387,"source":{"system":"sec-edgar","filing":"0001104659-26-108247","document":"tm2625479-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1368151/000110465926108247/tm2625479-1_4seq1.xml","form_type":"4"}},{"id":4619184,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76776,"kind":"person","name":"Capponi Vincent","position":1,"cik":"0001368151","reported_name":"Capponi Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2026-09-16T20:05:30.000Z","date":"2026-09-14","kind":"purchase","planned":false,"acquired":true,"shares":1800,"price":6.07,"value":10926.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (i) the following RSUs that will be settled into Common Stock upon vesting upon a \"Change In Control\" of CytoSorbents Corporation (the \"Issuer\") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (a) 505 RSUs granted on March 15, 2018, (b) 895 RSUs granted on February 24, 2017, (c) 2,700 RSUs granted on June 7, 2016 and (d) 6,250 RSUs granted on April 8, 2015;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (ii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 4,455 RSUs granted on August 8, 2025 and of which 2,228 remain unvested as of the date hereof; and"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iii) 25,736 shares of Common Stock owned by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026."}],"balance_after":40114,"source":{"system":"sec-edgar","filing":"0001104659-26-108247","document":"tm2625479-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368151/000110465926108247/tm2625479-1_4seq1.xml","form_type":"4"}},{"id":4619182,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76774,"kind":"person","name":"Sobel Alan D.","position":1,"cik":"0001639386","reported_name":"Sobel Alan D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-16T20:05:14.000Z","date":"2026-09-15","kind":"purchase","planned":false,"acquired":true,"shares":100,"price":6.01,"value":601.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These transactions reported on this Form 4 reflect open market purchases made by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (i) the following restricted stock units (\"RSUs\") that will be settled into Common Stock upon vesting upon a \"Change in Control\" of CytoSorbents Corporation (the \"Issuer\"), as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (a) 165 RSUs granted on March 15, 2018, (b) 300 RSUs granted on February 24, 2017, (c) 250 RSUs granted on June 7, 2016, and (d) 2,750 RSUs granted on April 8, 2015 and (ii) 6,422 shares of Common Stock owned directly by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026."}],"balance_after":9887,"source":{"system":"sec-edgar","filing":"0001104659-26-108246","document":"tm2625479-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1639386/000110465926108246/tm2625479-2_4seq1.xml","form_type":"4"}},{"id":4619181,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76774,"kind":"person","name":"Sobel Alan D.","position":1,"cik":"0001639386","reported_name":"Sobel Alan D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-16T20:05:14.000Z","date":"2026-09-15","kind":"purchase","planned":false,"acquired":true,"shares":500,"price":6.05,"value":3025.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These transactions reported on this Form 4 reflect open market purchases made by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (i) the following restricted stock units (\"RSUs\") that will be settled into Common Stock upon vesting upon a \"Change in Control\" of CytoSorbents Corporation (the \"Issuer\"), as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (a) 165 RSUs granted on March 15, 2018, (b) 300 RSUs granted on February 24, 2017, (c) 250 RSUs granted on June 7, 2016, and (d) 2,750 RSUs granted on April 8, 2015 and (ii) 6,422 shares of Common Stock owned directly by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026."}],"balance_after":9787,"source":{"system":"sec-edgar","filing":"0001104659-26-108246","document":"tm2625479-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1639386/000110465926108246/tm2625479-2_4seq1.xml","form_type":"4"}},{"id":4619180,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76774,"kind":"person","name":"Sobel Alan D.","position":1,"cik":"0001639386","reported_name":"Sobel Alan D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-16T20:05:14.000Z","date":"2026-09-15","kind":"purchase","planned":false,"acquired":true,"shares":1900,"price":6.12,"value":11628.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These transactions reported on this Form 4 reflect open market purchases made by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (i) the following restricted stock units (\"RSUs\") that will be settled into Common Stock upon vesting upon a \"Change in Control\" of CytoSorbents Corporation (the \"Issuer\"), as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (a) 165 RSUs granted on March 15, 2018, (b) 300 RSUs granted on February 24, 2017, (c) 250 RSUs granted on June 7, 2016, and (d) 2,750 RSUs granted on April 8, 2015 and (ii) 6,422 shares of Common Stock owned directly by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026."}],"balance_after":9287,"source":{"system":"sec-edgar","filing":"0001104659-26-108246","document":"tm2625479-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1639386/000110465926108246/tm2625479-2_4seq1.xml","form_type":"4"}},{"id":4613252,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":38283,"kind":"person","name":"Chan Phillip P.","position":1,"cik":"0001442786","reported_name":"Chan Phillip P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-09T20:05:14.000Z","date":"2026-09-04","kind":"purchase","planned":false,"acquired":true,"shares":200000,"price":0.35,"value":70000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person. The price reported in Column 4 is a weighted average\nprice. These shares were purchased in multiple transactions at prices ranging from $0.3470 to $0.3599, inclusive. The Reporting Person undertakes to provide to\nCytoSorbents Corporation (the \"Issuer\"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full\ninformation regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (i) the following restricted stock units (\"RSUs\") that will be settled into shares of Common Stock upon vesting upon a \"Change In Control\" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (ii) 52,800 RSUs of 105,600 granted on August 8, 2025, which vest in equal parts at the first and second year anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and (iii) 1,475,632 shares of Common Stock owned by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The shares reported herein were not adjusted to reflect the Issuer's reverse stock split that occurred on September 8, 2026."}],"balance_after":1944432,"source":{"system":"sec-edgar","filing":"0001104659-26-106308","document":"tm2625061-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442786/000110465926106308/tm2625061-1_4seq1.xml","form_type":"4"}},{"id":736566,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":37790,"kind":"person","name":"MARIANI PETER J","position":1,"cik":"0001222357","reported_name":"MARIANI PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-16T11:00:14.000Z","date":"2026-06-15","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":0.44,"value":44000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.40 to $0.45, inclusive. The Reporting Person undertakes to provide to CytoSorbents Corporation (the \"Issuer\"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (a) 110,000 restricted stock units (\"RSUs\"), which will be settled into the Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), upon vesting upon the earlier of (i) a \"Change In Control\" of the Issuer, as defined in the Reporting Person's employment agreement (the \"Employment Agreement\"), or (ii) the fourth anniversary from the date of grant, or August 14, 2028, subject to the Reporting Person's continued service as of the applicable vesting date;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (b) 65,000 RSUs, of which 32,500 remain unvested as of the date hereof, and which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (c) 175,000 RSUs, which will be settled into Common Stock upon a \"Change In Control\" of the Issuer, as defined in the Reporting Person's Employment Agreement, subject to the Reporting Person's continued service as of the applicable vesting date; (d) 71,500 RSUs, which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting; and"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (e) 216,613 shares of Common Stock owned by the Reporting Person."}],"balance_after":638113,"source":{"system":"sec-edgar","filing":"0001104659-26-074291","document":"tm2618022-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465926074291/tm2618022-1_4seq1.xml","form_type":"4"}},{"id":738188,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":38283,"kind":"person","name":"Chan Phillip P.","position":1,"cik":"0001442786","reported_name":"Chan Phillip P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-15T22:24:29.000Z","date":"2026-06-15","kind":"purchase","planned":false,"acquired":true,"shares":10333,"price":0.43,"value":4443.19,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The transaction reported on this Form 4 reflects an open market purchase made by the reporting person. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.4307 to $0.4388, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (i) the following restricted stock units (\"RSUs\") that will be settled into shares of Common Stock upon vesting upon a \"Change In Control\" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (iii) 105,600 RSUs granted on August 8, 2025, which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and (iv) 1,422,832 shares of Common Stock owned by the Reporting Person."}],"balance_after":1744432,"source":{"system":"sec-edgar","filing":"0001104659-26-074164","document":"tm2618008-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465926074164/tm2618008-1_4seq1.xml","form_type":"4"}},{"id":738187,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":38283,"kind":"person","name":"Chan Phillip P.","position":1,"cik":"0001442786","reported_name":"Chan Phillip P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-15T22:24:29.000Z","date":"2026-06-12","kind":"purchase","planned":false,"acquired":true,"shares":251136,"price":0.4,"value":100454.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.3885 to $0.40, inclusive. The Reporting Person undertakes to provide to CytoSorbents Corporation (the \"Issuer\"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (4) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (i) the following restricted stock units (\"RSUs\") that will be settled into shares of Common Stock upon vesting upon a \"Change In Control\" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (iii) 105,600 RSUs granted on August 8, 2025, which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and (iv) 1,422,832 shares of Common Stock owned by the Reporting Person."}],"balance_after":1734099,"source":{"system":"sec-edgar","filing":"0001104659-26-074164","document":"tm2618008-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465926074164/tm2618008-1_4seq1.xml","form_type":"4"}},{"id":992796,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":38283,"kind":"person","name":"Chan Phillip P.","position":1,"cik":"0001442786","reported_name":"Chan Phillip P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-11-21T02:09:45.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0.64,"value":64000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction reported on this Form 4 reflects an open market purchase made by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (i) the following restricted stock units (\"RSUs\") that will be settled into shares of Common Stock upon vesting upon a \"Change In Control\" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (iii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 96,000 RSUs granted on April 2, 2024 and of which 48,000 remain unvested as of the date hereof;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iv) 105,600 RSUs which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the\nreporting person's continued service as of the applicable vesting date, and (v) 1,113,363 shares of Common Stock owned by the Reporting Person."}],"balance_after":1482963,"source":{"system":"sec-edgar","filing":"0001104659-25-114706","document":"tm2531906-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925114706/tm2531906-1_4seq1.xml","form_type":"4"}},{"id":1071560,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":38283,"kind":"person","name":"Chan Phillip P.","position":1,"cik":"0001442786","reported_name":"Chan Phillip P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-08T23:40:26.000Z","date":"2025-08-08","kind":"grant","planned":false,"acquired":true,"shares":136400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date."}],"balance_after":136400,"derivative":{"exercise_price":1,"expiration_date":"2035-08-08","underlying":"Common Stock","underlying_shares":136400},"source":{"system":"sec-edgar","filing":"0001104659-25-075797","document":"tm2522995-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925075797/tm2522995-2_4seq1.xml","form_type":"4"}},{"id":1071559,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":38283,"kind":"person","name":"Chan Phillip P.","position":1,"cik":"0001442786","reported_name":"Chan Phillip P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-08-08T23:40:26.000Z","date":"2025-08-08","kind":"grant","planned":false,"acquired":true,"shares":105600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (i) the following RSUs that will be settled into shares of Common Stock upon vesting upon a \"Change In Control\" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (iii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 96,000 RSUs granted on April 2, 2024 and of which 48,000 remain unvested as of the date hereof; and"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iv) 1,013,363 shares of Common Stock owned by the Reporting Person."}],"balance_after":1382963,"source":{"system":"sec-edgar","filing":"0001104659-25-075797","document":"tm2522995-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925075797/tm2522995-2_4seq1.xml","form_type":"4"}},{"id":1071562,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76778,"kind":"person","name":"Jones Edward Raymond","position":1,"cik":"0001396246","reported_name":"Jones Edward Raymond","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-08T23:39:21.000Z","date":"2025-08-08","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options were granted pursuant to the Plan. The shares underlying the stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":1,"expiration_date":"2035-08-08","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001104659-25-075796","document":"tm2522995-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925075796/tm2522995-1_4seq1.xml","form_type":"4"}},{"id":1071561,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76777,"kind":"person","name":"BATOR MICHAEL G.","position":1,"cik":"0001647591","reported_name":"BATOR MICHAEL G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-08T23:38:11.000Z","date":"2025-08-08","kind":"grant","planned":false,"acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options were granted pursuant to the Plan. The shares underlying the stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date."}],"balance_after":44000,"derivative":{"exercise_price":1,"expiration_date":"2035-08-08","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001104659-25-075795","document":"tm2522995-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925075795/tm2522995-8_4seq1.xml","form_type":"4"}},{"id":1071558,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":37790,"kind":"person","name":"MARIANI PETER J","position":1,"cik":"0001222357","reported_name":"MARIANI PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-08T23:37:21.000Z","date":"2025-08-08","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date."}],"balance_after":90000,"derivative":{"exercise_price":1,"expiration_date":"2035-08-08","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001104659-25-075794","document":"tm2522995-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925075794/tm2522995-7_4seq1.xml","form_type":"4"}},{"id":1071557,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":37790,"kind":"person","name":"MARIANI PETER J","position":1,"cik":"0001222357","reported_name":"MARIANI PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-08T23:37:21.000Z","date":"2025-08-08","kind":"grant","planned":false,"acquired":true,"shares":71500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (a) 110,000 restricted stock units (\"RSUs\"), which will be settled into the Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), upon vesting upon the earlier of (i) a \"Change In Control\" of the Issuer, as defined in the Reporting Person's employment agreement (the \"Employment Agreement\"), or (ii) the fourth anniversary from the date of grant, or August 14, 2028, subject to the Reporting Person's continued service as of the applicable vesting date;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (b) 65,000 RSUs, which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (c) 175,000 RSUs, which will be settled into Common Stock upon a \"Change In Control\" of the Issuer, as defined in the Reporting Person's Employment Agreement, subject to the Reporting Person's continued service as of the applicable vesting date; and"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (d) 116,613 shares of Common Stock owned by the Reporting Person."}],"balance_after":538113,"source":{"system":"sec-edgar","filing":"0001104659-25-075794","document":"tm2522995-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925075794/tm2522995-7_4seq1.xml","form_type":"4"}},{"id":1071554,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76775,"kind":"person","name":"Kim Jiny","position":1,"cik":"0001920967","reported_name":"Kim Jiny","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-08T23:36:38.000Z","date":"2025-08-08","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options were granted pursuant to the Plan. The shares underlying the stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":1,"expiration_date":"2035-08-08","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001104659-25-075793","document":"tm2522995-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925075793/tm2522995-6_4seq1.xml","form_type":"4"}},{"id":1071556,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76776,"kind":"person","name":"Capponi Vincent","position":1,"cik":"0001368151","reported_name":"Capponi Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-08T23:35:15.000Z","date":"2025-08-08","kind":"grant","planned":false,"acquired":true,"shares":111100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date."}],"balance_after":111100,"derivative":{"exercise_price":1,"expiration_date":"2035-08-08","underlying":"Common Stock","underlying_shares":111100},"source":{"system":"sec-edgar","filing":"0001104659-25-075792","document":"tm2522995-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925075792/tm2522995-4_4seq1.xml","form_type":"4"}},{"id":1071555,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76776,"kind":"person","name":"Capponi Vincent","position":1,"cik":"0001368151","reported_name":"Capponi Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2025-08-08T23:35:15.000Z","date":"2025-08-08","kind":"grant","planned":false,"acquired":true,"shares":89100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (i) the following RSUs that will be settled into Common Stock upon vesting upon a \"Change In Control\" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (a) 10,100 RSUs granted on March 15, 2018, (b) 17,900 RSUs granted on February 24, 2017, (c) 54,000 RSUs granted on June 7, 2016 and (d) 125,000 RSUs granted on April 8, 2015;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (ii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 81,000 RSUs granted on April 2, 2024 and of which 40,500 remain unvested as of the date hereof; and"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iii) 429,668 shares of Common Stock owned by the Reporting Person."}],"balance_after":766268,"source":{"system":"sec-edgar","filing":"0001104659-25-075792","document":"tm2522995-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925075792/tm2522995-4_4seq1.xml","form_type":"4"}},{"id":1071552,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76773,"kind":"person","name":"Deliargyris Efthymios","position":1,"cik":"0001751617","reported_name":"Deliargyris Efthymios","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-08T23:34:26.000Z","date":"2025-08-08","kind":"grant","planned":false,"acquired":true,"shares":95000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date."}],"balance_after":95000,"derivative":{"exercise_price":1,"expiration_date":"2035-08-08","underlying":"Common Stock","underlying_shares":95000},"source":{"system":"sec-edgar","filing":"0001104659-25-075791","document":"tm2522995-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925075791/tm2522995-3_4seq1.xml","form_type":"4"}},{"id":1071551,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76773,"kind":"person","name":"Deliargyris Efthymios","position":1,"cik":"0001751617","reported_name":"Deliargyris Efthymios","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-08-08T23:34:26.000Z","date":"2025-08-08","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (ii) the following RSUs that will be settled into Common Stock upon vesting upon a \"Change In Control\" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (a) 120,000 RSUs granted on April 9, 2020 and (b) 55,000 RSUs granted on August 10, 2022;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (iii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 61,000 RSUs granted on April 2, 2024 and of which 30,500 remain unvested as of the date hereof; and"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iv) 197,525 shares of Common Stock owned by the reporting person."}],"balance_after":473025,"source":{"system":"sec-edgar","filing":"0001104659-25-075791","document":"tm2522995-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925075791/tm2522995-3_4seq1.xml","form_type":"4"}},{"id":1071553,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76774,"kind":"person","name":"Sobel Alan D.","position":1,"cik":"0001639386","reported_name":"Sobel Alan D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-08T23:33:14.000Z","date":"2025-08-08","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options were granted pursuant to the Plan. The shares underlying the stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":1,"expiration_date":"2035-08-08","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001104659-25-075790","document":"tm2522995-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925075790/tm2522995-5_4seq1.xml","form_type":"4"}},{"id":1230408,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76777,"kind":"person","name":"BATOR MICHAEL G.","position":1,"cik":"0001647591","reported_name":"BATOR MICHAEL G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Right Warrants (right to buy)","published_at":"2025-03-05T02:00:21.000Z","date":"2025-02-24","kind":"other","planned":false,"acquired":false,"shares":15879,"price":1.13,"value":17943.27,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 17, 2025, the Reporting Person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the Reporting Person received Units consisting of an aggregate of 15,879 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $15,879. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Right Warrants exercise price was calculated as 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The Reporting Person's remaining 5,879 Series A Warrants expired unexercised on February 24, 2025."}],"balance_after":0,"derivative":{"exercise_price":1.13,"exercise_date":"2025-01-17","expiration_date":"2025-02-24","underlying":"Common Stock","underlying_shares":15879},"source":{"system":"sec-edgar","filing":"0001104659-25-020516","document":"tm257709-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925020516/tm257709-2_4seq1.xml","form_type":"4"}},{"id":1230407,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76777,"kind":"person","name":"BATOR MICHAEL G.","position":1,"cik":"0001647591","reported_name":"BATOR MICHAEL G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-05T02:00:21.000Z","date":"2025-02-24","kind":"other","planned":false,"acquired":true,"shares":10000,"price":1.13,"value":11300.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 17, 2025, the Reporting Person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the Reporting Person received Units consisting of an aggregate of 15,879 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $15,879. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A Right Warrants exercise price was calculated as 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes (a) the following restricted stock units (\"RSUs\") which will vest upon a \"Change of Control\" of the Company, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (i) 3,300 RSUs granted on March 15, 2018, (ii) 6,000 RSUs granted on February 24, 2017, and (iii) 60,000 RSUs granted on June 7, 2016, and (b) 81,973 shares of Common Stock owned by the Reporting Person."}],"balance_after":151273,"source":{"system":"sec-edgar","filing":"0001104659-25-020516","document":"tm257709-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925020516/tm257709-2_4seq1.xml","form_type":"4"}},{"id":1243709,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76776,"kind":"person","name":"Capponi Vincent","position":1,"cik":"0001368151","reported_name":"Capponi Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Series A Right Warrants (right to buy)","published_at":"2025-02-27T00:29:54.000Z","date":"2025-02-24","kind":"other","planned":false,"acquired":false,"shares":12000,"price":1.13,"value":13560.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 17, 2025, the Reporting Person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the Reporting Person received Units consisting of an aggregate of 31,760 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $31,760. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Right Warrants exercise price was calculated as 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The Reporting Person's remaining 19,760 Series A Warrants expired unexercised on February 24, 2025."}],"balance_after":0,"derivative":{"exercise_price":1.13,"exercise_date":"2025-01-17","expiration_date":"2025-02-24","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001104659-25-017621","document":"tm257709-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925017621/tm257709-4_4seq1.xml","form_type":"4"}},{"id":1243708,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76776,"kind":"person","name":"Capponi Vincent","position":1,"cik":"0001368151","reported_name":"Capponi Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2025-02-27T00:29:54.000Z","date":"2025-02-24","kind":"other","planned":false,"acquired":true,"shares":12000,"price":1.13,"value":13560.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 17, 2025, the Reporting Person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the Reporting Person received Units consisting of an aggregate of 31,760 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $31,760. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A Right Warrants exercise price was calculated as 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes: (i) the following RSUs, which vest as to two-thirds of the award on the first year anniversary of the date of grant and one-third of the award on the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date) and will settle into shares of common stock, par value $0.001 per share (the \"Common Stock\"), of the Company upon vesting: 73,000 RSUs granted on July 7, 2023 and of which 24,334 RSUs remain unvested as of the date hereof;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (ii) the following RSUs that will be settled into Common Stock upon vesting upon a \"Change In Control\" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (a) 10,100 RSUs granted on March 15, 2018, (b) 17,900 RSUs granted on February 24, 2017, (c) 54,000 RSUs granted on June 7, 2016 and (d) 125,000 RSUs granted on April 8, 2015;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (iii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 81,000 RSUs granted on April 2, 2024 and remain unvested as of the date hereof; and 5. (continued from footnote 4) (iv) 364,834 shares of Common Stock owned by the Reporting Person."}],"balance_after":677168,"source":{"system":"sec-edgar","filing":"0001104659-25-017621","document":"tm257709-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925017621/tm257709-4_4seq1.xml","form_type":"4"}},{"id":1243705,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":37790,"kind":"person","name":"MARIANI PETER J","position":1,"cik":"0001222357","reported_name":"MARIANI PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Series A Right Warrants (right to buy)","published_at":"2025-02-27T00:28:35.000Z","date":"2025-02-24","kind":"other","planned":false,"acquired":false,"shares":32625,"price":1.13,"value":36866.25,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 17, 2025, the Reporting Person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the Reporting Person received Units consisting of an aggregate of 32,625 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $32,625. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Right Warrants exercise price was calculated as 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00."}],"balance_after":0,"derivative":{"exercise_price":1.13,"exercise_date":"2025-01-17","expiration_date":"2025-02-24","underlying":"Common Stock","underlying_shares":32625},"source":{"system":"sec-edgar","filing":"0001104659-25-017620","document":"tm257709-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925017620/tm257709-3_4seq1.xml","form_type":"4"}},{"id":1243704,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":37790,"kind":"person","name":"MARIANI PETER J","position":1,"cik":"0001222357","reported_name":"MARIANI PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-27T00:28:35.000Z","date":"2025-02-24","kind":"other","planned":false,"acquired":true,"shares":32625,"price":1.13,"value":36866.25,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 17, 2025, the Reporting Person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the Reporting Person received Units consisting of an aggregate of 32,625 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $32,625. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A Right Warrants exercise price was calculated as 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes (a) 110,000 restricted stock units (\"RSUs\"), which will be settled into the Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), upon vesting upon the earlier of (i) a \"Change In Control\" of the Issuer, as defined in the Reporting Person's employment agreement (the \"Employment Agreement\"), or (ii) the fourth anniversary from the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (b) 65,000 RSUs, which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (c) 175,000 RSUs, which will be settled into Common Stock upon a \"Change In Control\" of the Issuer, as defined in the Reporting Person's Employment Agreement, subject to the Reporting Person's continued service as of the applicable vesting date; and"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"(continued from footnote 5) (d) 116,613 shares of Common Stock owned by the Reporting Person."}],"balance_after":466613,"source":{"system":"sec-edgar","filing":"0001104659-25-017620","document":"tm257709-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925017620/tm257709-3_4seq1.xml","form_type":"4"}},{"id":1243707,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":38283,"kind":"person","name":"Chan Phillip P.","position":1,"cik":"0001442786","reported_name":"Chan Phillip P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series A Right Warrants (right to buy)","published_at":"2025-02-27T00:27:36.000Z","date":"2025-02-24","kind":"other","planned":false,"acquired":false,"shares":34168,"price":1.13,"value":38609.84,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 17, 2025, the Reporting Person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the Reporting Person received Units consisting of an aggregate of 90,832 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $90,832. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Right Warrants exercise price was calculated as 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"The Reporting Person's remaining 56,664 Series A Warrants expired unexercised on February 24, 2025."}],"balance_after":0,"derivative":{"exercise_price":1.13,"exercise_date":"2025-01-17","expiration_date":"2025-02-24","underlying":"Common Stock","underlying_shares":34168},"source":{"system":"sec-edgar","filing":"0001104659-25-017619","document":"tm257709-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925017619/tm257709-1_4seq1.xml","form_type":"4"}},{"id":1243706,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":38283,"kind":"person","name":"Chan Phillip P.","position":1,"cik":"0001442786","reported_name":"Chan Phillip P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-27T00:27:36.000Z","date":"2025-02-24","kind":"other","planned":false,"acquired":true,"shares":34168,"price":1.13,"value":38609.84,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 17, 2025, the Reporting Person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the Reporting Person received Units consisting of an aggregate of 90,832 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $90,832. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A Right Warrants exercise price was calculated as 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes: (i) the following RSUs, which vest as to two-thirds of the award on the first year anniversary of the date of grant and one-third of the award on the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of common stock, par value $0.001 per share (the \"Common Stock\"), of the Company upon vesting: 87,000 RSUs granted on July 7, 2023 and of which 29,000 RSUs remain unvested as of the date hereof;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (ii) the following RSUs that will be settled into shares of Common Stock upon vesting upon a \"Change In Control\" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (iii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 96,000 RSUs granted on April 2, 2024 and remain unvested as of the date hereof; and"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"(continued from footnote 5) (iv) 936,363 shares of Common Stock owned by the Reporting Person."}],"balance_after":1277363,"source":{"system":"sec-edgar","filing":"0001104659-25-017619","document":"tm257709-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925017619/tm257709-1_4seq1.xml","form_type":"4"}},{"id":1243702,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76774,"kind":"person","name":"Sobel Alan D.","position":1,"cik":"0001639386","reported_name":"Sobel Alan D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Right Warrants (right to buy)","published_at":"2025-02-27T00:26:40.000Z","date":"2025-02-24","kind":"other","planned":false,"acquired":false,"shares":21950,"price":1.13,"value":24803.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 17, 2025, the Reporting Person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the Reporting Person received Units consisting of an aggregate of 21,950 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $21,950. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Right Warrants exercise price was calculated as 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00."}],"balance_after":0,"derivative":{"exercise_price":1.13,"exercise_date":"2025-01-17","expiration_date":"2025-02-24","underlying":"Common Stock","underlying_shares":21950},"source":{"system":"sec-edgar","filing":"0001104659-25-017618","document":"tm257709-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925017618/tm257709-5_4seq1.xml","form_type":"4"}},{"id":1243701,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76774,"kind":"person","name":"Sobel Alan D.","position":1,"cik":"0001639386","reported_name":"Sobel Alan D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-27T00:26:40.000Z","date":"2025-02-24","kind":"other","planned":false,"acquired":true,"shares":21950,"price":1.13,"value":24803.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 17, 2025, the Reporting Person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the Reporting Person received Units consisting of an aggregate of 21,950 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $21,950. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A Right Warrants exercise price was calculated as 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes (i) the following restricted stock units (\"RSUs\") that will be settled into Common Stock upon vesting upon a \"Change in Control\" of the Company, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (a) 3,300 RSUs granted on March 15, 2018, (b) 6,000 RSUs granted on February 24, 2017, (c) 5,000 RSUs granted on June 7, 2016, and (d) 55,000 RSUs granted on April 8, 2015 and (ii) 76,457 shares of Common Stock owned directly by the Reporting Person."}],"balance_after":145757,"source":{"system":"sec-edgar","filing":"0001104659-25-017618","document":"tm257709-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925017618/tm257709-5_4seq1.xml","form_type":"4"}},{"id":1298009,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76777,"kind":"person","name":"BATOR MICHAEL G.","position":1,"cik":"0001647591","reported_name":"BATOR MICHAEL G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Right Warrants","published_at":"2025-01-23T01:35:13.000Z","date":"2025-01-17","kind":"other","planned":false,"acquired":true,"shares":15879,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 15,879 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $15,879.  The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Series B Right Warrants expire 90 calendar days following the Closing Date."}],"balance_after":15879,"derivative":{"exercise_date":"2025-01-17","expiration_date":"2025-04-10","underlying":"Common Stock","underlying_shares":15879},"source":{"system":"sec-edgar","filing":"0001104659-25-005358","document":"tm254168-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925005358/tm254168-5_4seq1.xml","form_type":"4"}},{"id":1298008,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76777,"kind":"person","name":"BATOR MICHAEL G.","position":1,"cik":"0001647591","reported_name":"BATOR MICHAEL G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Right Warrants","published_at":"2025-01-23T01:35:13.000Z","date":"2025-01-17","kind":"other","planned":false,"acquired":true,"shares":15879,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 15,879 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $15,879.  The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series A Right Warrants expire 45 calendar days following the Closing Date."}],"balance_after":15879,"derivative":{"exercise_date":"2025-01-17","expiration_date":"2025-02-24","underlying":"Common Stock","underlying_shares":15879},"source":{"system":"sec-edgar","filing":"0001104659-25-005358","document":"tm254168-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925005358/tm254168-5_4seq1.xml","form_type":"4"}},{"id":1298007,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76777,"kind":"person","name":"BATOR MICHAEL G.","position":1,"cik":"0001647591","reported_name":"BATOR MICHAEL G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Subscription Rights (right to buy)","published_at":"2025-01-23T01:35:13.000Z","date":"2025-01-17","kind":"other","planned":false,"acquired":false,"shares":15879,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 15,879 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $15,879.  The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."}],"balance_after":0,"derivative":{"exercise_price":1,"exercise_date":"2024-12-09","expiration_date":"2025-01-10","underlying":"Common Stock","underlying_shares":15879},"source":{"system":"sec-edgar","filing":"0001104659-25-005358","document":"tm254168-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925005358/tm254168-5_4seq1.xml","form_type":"4"}},{"id":1298006,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76777,"kind":"person","name":"BATOR MICHAEL G.","position":1,"cik":"0001647591","reported_name":"BATOR MICHAEL G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-23T01:35:13.000Z","date":"2025-01-17","kind":"other","planned":false,"acquired":true,"shares":15879,"price":1,"value":15879.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 15,879 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $15,879.  The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 15,879 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $15,879.  The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (a) the following restricted stock units (\"RSUs\") which will vest upon a \"Change of Control\" of the Company, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (i) 3,300 RSUs granted on March 15, 2018, (ii) 6,000 RSUs granted on February 24, 2017, and (iii) 60,000 RSUs granted on June 7, 2016, and (b) 56,094 shares of Common Stock owned by the reporting person."}],"balance_after":141273,"source":{"system":"sec-edgar","filing":"0001104659-25-005358","document":"tm254168-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925005358/tm254168-5_4seq1.xml","form_type":"4"}},{"id":1298005,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76776,"kind":"person","name":"Capponi Vincent","position":1,"cik":"0001368151","reported_name":"Capponi Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Series B Right Warrants","published_at":"2025-01-23T01:34:26.000Z","date":"2025-01-17","kind":"other","planned":false,"acquired":true,"shares":31760,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 31,760 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $31,760. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The Series B Right Warrants expire 90 calendar days following the Closing Date."}],"balance_after":31760,"derivative":{"exercise_date":"2025-01-17","expiration_date":"2025-04-10","underlying":"Common Stock","underlying_shares":31760},"source":{"system":"sec-edgar","filing":"0001104659-25-005356","document":"tm254168-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925005356/tm254168-3_4seq1.xml","form_type":"4"}},{"id":1298004,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76776,"kind":"person","name":"Capponi Vincent","position":1,"cik":"0001368151","reported_name":"Capponi Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Series A Right Warrants","published_at":"2025-01-23T01:34:26.000Z","date":"2025-01-17","kind":"other","planned":false,"acquired":true,"shares":31760,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 31,760 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $31,760. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Series A Right Warrants expire 45 calendar days following the Closing Date."}],"balance_after":31760,"derivative":{"exercise_date":"2025-01-17","expiration_date":"2025-02-24","underlying":"Common Stock","underlying_shares":31760},"source":{"system":"sec-edgar","filing":"0001104659-25-005356","document":"tm254168-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925005356/tm254168-3_4seq1.xml","form_type":"4"}},{"id":1298003,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76776,"kind":"person","name":"Capponi Vincent","position":1,"cik":"0001368151","reported_name":"Capponi Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Subscription Rights (right to buy)","published_at":"2025-01-23T01:34:26.000Z","date":"2025-01-17","kind":"other","planned":false,"acquired":false,"shares":31760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 31,760 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $31,760. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."}],"balance_after":0,"derivative":{"exercise_price":1,"exercise_date":"2024-12-09","expiration_date":"2025-01-10","underlying":"Common Stock","underlying_shares":31760},"source":{"system":"sec-edgar","filing":"0001104659-25-005356","document":"tm254168-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925005356/tm254168-3_4seq1.xml","form_type":"4"}},{"id":1298002,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76776,"kind":"person","name":"Capponi Vincent","position":1,"cik":"0001368151","reported_name":"Capponi Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2025-01-23T01:34:26.000Z","date":"2025-01-17","kind":"other","planned":false,"acquired":true,"shares":31760,"price":1,"value":31760.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 31,760 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $31,760. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 31,760 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $31,760. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (i) the following RSUs, which vest as to two-thirds of the award on the first year anniversary of the date of grant and one-third of the award on the second year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of common stock, par value $0.001 per share (the \"Common Stock\"), of the Company upon vesting: 73,000 RSUs granted on July 7, 2023 and of which 24,334 RSUs remain unvested as of the date hereof;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon vesting upon a \"Change In Control\" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (a) 10,100 RSUs granted on March 15, 2018, (b) 17,900 RSUs granted on February 24, 2017, (c) 54,000 RSUs granted on June 7, 2016 and (d) 125,000 RSUs granted on April 8, 2015;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 81,000 RSUs granted on April 2, 2024 and remain unvested as of the date hereof; and"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (iv) 352,834 shares of Common Stock owned by the reporting person."}],"balance_after":665168,"source":{"system":"sec-edgar","filing":"0001104659-25-005356","document":"tm254168-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925005356/tm254168-3_4seq1.xml","form_type":"4"}},{"id":1298001,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76773,"kind":"person","name":"Deliargyris Efthymios","position":1,"cik":"0001751617","reported_name":"Deliargyris Efthymios","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Series B Right Warrants","published_at":"2025-01-23T01:33:08.000Z","date":"2025-01-17","kind":"other","planned":false,"acquired":true,"shares":16233,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 16,233 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $16,233. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The Series B Right Warrants expire 90 calendar days following the Closing Date."}],"balance_after":16233,"derivative":{"exercise_date":"2025-01-17","expiration_date":"2025-04-10","underlying":"Common Stock","underlying_shares":16233},"source":{"system":"sec-edgar","filing":"0001104659-25-005355","document":"tm254168-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925005355/tm254168-2_4seq1.xml","form_type":"4"}},{"id":1298000,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76773,"kind":"person","name":"Deliargyris Efthymios","position":1,"cik":"0001751617","reported_name":"Deliargyris Efthymios","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Series A Right Warrants","published_at":"2025-01-23T01:33:08.000Z","date":"2025-01-17","kind":"other","planned":false,"acquired":true,"shares":16233,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 16,233 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $16,233. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Series A Right Warrants expire 45 calendar days following the Closing Date."}],"balance_after":16233,"derivative":{"exercise_date":"2025-01-17","expiration_date":"2025-02-24","underlying":"Common Stock","underlying_shares":16233},"source":{"system":"sec-edgar","filing":"0001104659-25-005355","document":"tm254168-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925005355/tm254168-2_4seq1.xml","form_type":"4"}},{"id":1297999,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76773,"kind":"person","name":"Deliargyris Efthymios","position":1,"cik":"0001751617","reported_name":"Deliargyris Efthymios","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Subscription Rights (right to buy)","published_at":"2025-01-23T01:33:08.000Z","date":"2025-01-17","kind":"other","planned":false,"acquired":false,"shares":16233,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 16,233 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $16,233. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."}],"balance_after":0,"derivative":{"exercise_price":1,"exercise_date":"2024-12-09","expiration_date":"2025-01-10","underlying":"Common Stock","underlying_shares":16233},"source":{"system":"sec-edgar","filing":"0001104659-25-005355","document":"tm254168-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925005355/tm254168-2_4seq1.xml","form_type":"4"}},{"id":1297998,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76773,"kind":"person","name":"Deliargyris Efthymios","position":1,"cik":"0001751617","reported_name":"Deliargyris Efthymios","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-23T01:33:08.000Z","date":"2025-01-17","kind":"other","planned":false,"acquired":true,"shares":16233,"price":1,"value":16233.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 16,233 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $16,233. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 16,233 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $16,233. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (i) the following RSUs, which vest as to two-thirds of the award on the first anniversary of the date of grant and one-third of the award on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) that will settle into shares of common stock, par value $0.001 per share (the \"Common Stock\") upon vesting: 55,000 RSUs granted on July 7, 2023 and of which 18,334 RSUs remain unvested as of the date hereof;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon vesting upon a \"Change In Control\" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (a) 120,000 RSUs granted on April 9, 2020 and (b) 55,000 RSUs granted on August 10, 2022;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 61,000 RSUs granted on April 2, 2024 and remain unvested as of the date hereof; and"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (iv) 148,691 shares of Common Stock owned by the reporting person."}],"balance_after":403025,"source":{"system":"sec-edgar","filing":"0001104659-25-005355","document":"tm254168-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925005355/tm254168-2_4seq1.xml","form_type":"4"}},{"id":1297997,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76774,"kind":"person","name":"Sobel Alan D.","position":1,"cik":"0001639386","reported_name":"Sobel Alan D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Right Warrants","published_at":"2025-01-23T01:32:16.000Z","date":"2025-01-17","kind":"other","planned":false,"acquired":true,"shares":21950,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 21,950 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $21,950.  The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Series B Right Warrants expire 90 calendar days following the Closing Date."}],"balance_after":21950,"derivative":{"exercise_date":"2025-01-17","expiration_date":"2025-04-10","underlying":"Common Stock","underlying_shares":21950},"source":{"system":"sec-edgar","filing":"0001104659-25-005354","document":"tm254168-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925005354/tm254168-1_4seq1.xml","form_type":"4"}},{"id":1297996,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76774,"kind":"person","name":"Sobel Alan D.","position":1,"cik":"0001639386","reported_name":"Sobel Alan D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Right Warrants","published_at":"2025-01-23T01:32:16.000Z","date":"2025-01-17","kind":"other","planned":false,"acquired":true,"shares":21950,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 21,950 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $21,950.  The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series A Right Warrants expire 45 calendar days following the Closing Date."}],"balance_after":21950,"derivative":{"exercise_date":"2025-01-17","expiration_date":"2025-02-24","underlying":"Common Stock","underlying_shares":21950},"source":{"system":"sec-edgar","filing":"0001104659-25-005354","document":"tm254168-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925005354/tm254168-1_4seq1.xml","form_type":"4"}},{"id":1297995,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76774,"kind":"person","name":"Sobel Alan D.","position":1,"cik":"0001639386","reported_name":"Sobel Alan D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Subscription Rights (right to buy)","published_at":"2025-01-23T01:32:16.000Z","date":"2025-01-17","kind":"other","planned":false,"acquired":false,"shares":21950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 21,950 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $21,950.  The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."}],"balance_after":0,"derivative":{"exercise_price":1,"exercise_date":"2024-12-09","expiration_date":"2025-01-10","underlying":"Common Stock","underlying_shares":21950},"source":{"system":"sec-edgar","filing":"0001104659-25-005354","document":"tm254168-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925005354/tm254168-1_4seq1.xml","form_type":"4"}},{"id":1297994,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76774,"kind":"person","name":"Sobel Alan D.","position":1,"cik":"0001639386","reported_name":"Sobel Alan D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-23T01:32:16.000Z","date":"2025-01-17","kind":"other","planned":false,"acquired":true,"shares":21950,"price":1,"value":21950.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 21,950 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $21,950.  The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 21,950 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $21,950.  The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (i) the following restricted stock units (\"RSUs\") that will be settled into Common Stock upon vesting upon a \"Change in Control\" of the Company, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (a) 3,300 RSUs granted on March 15, 2018, (b) 6,000 RSUs granted on February 24, 2017, (c) 5,000 RSUs granted on June 7, 2016, and (d) 55,000 RSUs granted on April 8, 2015 and (ii) 32,557 shares of Common Stock owned directly by the reporting person."}],"balance_after":123807,"source":{"system":"sec-edgar","filing":"0001104659-25-005354","document":"tm254168-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925005354/tm254168-1_4seq1.xml","form_type":"4"}},{"id":1297989,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":38283,"kind":"person","name":"Chan Phillip P.","position":1,"cik":"0001442786","reported_name":"Chan Phillip P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series B Right Warrants","published_at":"2025-01-23T01:31:03.000Z","date":"2025-01-17","kind":"other","planned":false,"acquired":true,"shares":90832,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 90,832 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $90,832. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The Series B Right Warrants expire 90 calendar days following the Closing Date."}],"balance_after":90832,"derivative":{"exercise_date":"2025-01-17","expiration_date":"2025-04-10","underlying":"Common Stock","underlying_shares":90832},"source":{"system":"sec-edgar","filing":"0001104659-25-005353","document":"tm254168-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925005353/tm254168-4_4seq1.xml","form_type":"4"}},{"id":1297988,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":38283,"kind":"person","name":"Chan Phillip P.","position":1,"cik":"0001442786","reported_name":"Chan Phillip P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series A Right Warrants","published_at":"2025-01-23T01:31:03.000Z","date":"2025-01-17","kind":"other","planned":false,"acquired":true,"shares":90832,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 90,832 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $90,832. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Series A Right Warrants expire 45 calendar days following the Closing Date."}],"balance_after":90832,"derivative":{"exercise_date":"2025-01-17","expiration_date":"2025-02-24","underlying":"Common Stock","underlying_shares":90832},"source":{"system":"sec-edgar","filing":"0001104659-25-005353","document":"tm254168-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925005353/tm254168-4_4seq1.xml","form_type":"4"}},{"id":1297987,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":38283,"kind":"person","name":"Chan Phillip P.","position":1,"cik":"0001442786","reported_name":"Chan Phillip P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Subscription Rights (right to buy)","published_at":"2025-01-23T01:31:03.000Z","date":"2025-01-17","kind":"other","planned":false,"acquired":false,"shares":90832,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 90,832 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $90,832. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."}],"balance_after":0,"derivative":{"exercise_price":1,"exercise_date":"2024-12-09","expiration_date":"2025-01-10","underlying":"Common Stock","underlying_shares":90832},"source":{"system":"sec-edgar","filing":"0001104659-25-005353","document":"tm254168-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925005353/tm254168-4_4seq1.xml","form_type":"4"}},{"id":1297986,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":38283,"kind":"person","name":"Chan Phillip P.","position":1,"cik":"0001442786","reported_name":"Chan Phillip P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-23T01:31:03.000Z","date":"2025-01-17","kind":"other","planned":false,"acquired":true,"shares":90832,"price":1,"value":90832.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 90,832 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $90,832. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 90,832 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $90,832. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (i) the following RSUs, which vest as to two-thirds of the award on the first year anniversary of the date of grant and one-third of the award on the second year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will settle into shares of common stock, par value $0.001 per share (the \"Common Stock\"), of the Company upon vesting: 87,000 RSUs granted on July 7, 2023 and of which 29,000 RSUs remain unvested as of the date hereof;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (ii) the following RSUs that will be settled into shares of Common Stock upon vesting upon a \"Change In Control\" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 96,000 RSUs granted on April 2, 2024 and remain unvested as of the date hereof; and"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (iv) 902,195 shares of Common Stock owned by the reporting person."}],"balance_after":1243195,"source":{"system":"sec-edgar","filing":"0001104659-25-005353","document":"tm254168-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925005353/tm254168-4_4seq1.xml","form_type":"4"}},{"id":1297993,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":37790,"kind":"person","name":"MARIANI PETER J","position":1,"cik":"0001222357","reported_name":"MARIANI PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Series B Right Warrants","published_at":"2025-01-23T01:29:46.000Z","date":"2025-01-17","kind":"other","planned":false,"acquired":true,"shares":32625,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 32,625 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $32,625. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The Series B Right Warrants expire 90 calendar days following the Closing Date."}],"balance_after":32625,"derivative":{"exercise_date":"2025-01-17","expiration_date":"2025-04-10","underlying":"Common Stock","underlying_shares":32625},"source":{"system":"sec-edgar","filing":"0001104659-25-005352","document":"tm254168-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925005352/tm254168-6_4seq1.xml","form_type":"4"}},{"id":1297992,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":37790,"kind":"person","name":"MARIANI PETER J","position":1,"cik":"0001222357","reported_name":"MARIANI PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Series A Right Warrants","published_at":"2025-01-23T01:29:46.000Z","date":"2025-01-17","kind":"other","planned":false,"acquired":true,"shares":32625,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 32,625 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $32,625. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Series A Right Warrants expire 45 calendar days following the Closing Date."}],"balance_after":32625,"derivative":{"exercise_date":"2025-01-17","expiration_date":"2025-02-24","underlying":"Common Stock","underlying_shares":32625},"source":{"system":"sec-edgar","filing":"0001104659-25-005352","document":"tm254168-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925005352/tm254168-6_4seq1.xml","form_type":"4"}},{"id":1297991,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":37790,"kind":"person","name":"MARIANI PETER J","position":1,"cik":"0001222357","reported_name":"MARIANI PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Subscription Rights (right to buy)","published_at":"2025-01-23T01:29:46.000Z","date":"2025-01-17","kind":"other","planned":false,"acquired":false,"shares":32625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 32,625 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $32,625. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."}],"balance_after":0,"derivative":{"exercise_price":1,"exercise_date":"2024-12-09","expiration_date":"2025-01-10","underlying":"Common Stock","underlying_shares":32625},"source":{"system":"sec-edgar","filing":"0001104659-25-005352","document":"tm254168-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925005352/tm254168-6_4seq1.xml","form_type":"4"}},{"id":1297990,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":37790,"kind":"person","name":"MARIANI PETER J","position":1,"cik":"0001222357","reported_name":"MARIANI PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-23T01:29:46.000Z","date":"2025-01-17","kind":"other","planned":false,"acquired":true,"shares":32625,"price":1,"value":32625.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 32,625 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $32,625. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the \"Rights Offering\") with CytoSorbents Corporation (the \"Issuer\") whereby the reporting person received Units consisting of an aggregate of 32,625 (i) shares of Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $32,625. The Rights Offering closed on January 10, 2025 (the \"Closing Date\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (a) 110,000 restricted stock units (\"RSUs\"), which will be settled into the Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), upon vesting upon the earlier of (i) a \"Change In Control\" of the Issuer, as defined in the Reporting Person's employment agreement (the \"Employment Agreement\"), or (ii) the fourth anniversary from the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (b) 65,000 RSUs, which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (c) 175,000 RSUs, which will be settled into Common Stock upon a \"Change In Control\" of the Issuer, as defined in the Reporting Person's Employment Agreement, subject to the Reporting Person's continued service as of the applicable vesting date; and"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (d) 83,988 shares of Common Stock owned by the Reporting Person."}],"balance_after":433988,"source":{"system":"sec-edgar","filing":"0001104659-25-005352","document":"tm254168-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925005352/tm254168-6_4seq1.xml","form_type":"4"}},{"id":1331153,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":37790,"kind":"person","name":"MARIANI PETER J","position":1,"cik":"0001222357","reported_name":"MARIANI PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-12-16T12:00:11.000Z","date":"2024-12-13","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":0.9647,"value":19294.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects open market purchases made by the Reporting Person. The price reported in Column 4 is the weighted average price of purchases made in multiple transactions at prices ranging from $0.8902 to $1.09. The Reporting Person undertakes to provide full information regarding the number of shares purchased at each separate price within the range set forth herein upon request."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects open market purchases made by the Reporting Person. The price reported in Column 4 is the weighted average price of purchases made in multiple transactions at prices ranging from $0.8902 to $1.09. The Reporting Person undertakes to provide full information regarding the number of shares purchased at each separate price within the range set forth herein upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (a) 110,000 restricted stock units (\"RSUs\"), which will be settled into the Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), upon vesting upon the earlier of (i) a \"Change In Control\" of the Issuer, as defined in the Reporting Person's employment agreement (the \"Employment Agreement\"), or (ii) the fourth anniversary from the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (b) 65,000 RSUs, which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (c) 175,000 RSUs, which will be settled into Common Stock upon a \"Change In Control\" of the Issuer, as defined in the Reporting Person's Employment Agreement, subject to the Reporting Person's continued service as of the applicable vesting date; and"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (d) 51,363 shares of Common Stock owned by the Reporting Person."}],"balance_after":401363,"source":{"system":"sec-edgar","filing":"0001104659-24-128667","document":"tm2431157-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924128667/tm2431157-1_4seq1.xml","form_type":"4"}},{"id":1332718,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":37790,"kind":"person","name":"MARIANI PETER J","position":1,"cik":"0001222357","reported_name":"MARIANI PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-12-13T13:00:13.000Z","date":"2024-12-12","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":0.8936,"value":17872.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects open market purchases made by the Reporting Person. The price reported in Column 4 is the weighted average price of purchases made in multiple transactions at prices ranging from $0.88 to $0.90. The Reporting Person undertakes to provide full information regarding the number of shares purchased at each separate price within the range set forth herein upon request."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects open market purchases made by the Reporting Person. The price reported in Column 4 is the weighted average price of purchases made in multiple transactions at prices ranging from $0.88 to $0.90. The Reporting Person undertakes to provide full information regarding the number of shares purchased at each separate price within the range set forth herein upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes (a) 110,000 restricted stock units (\"RSUs\"), which will be settled into the Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), upon vesting upon the earlier of (i) a \"Change In Control\" of the Issuer, as defined in the Reporting Person's employment agreement (the \"Employment Agreement\"), or (ii) the fourth anniversary from the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (b) 65,000 RSUs, which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (c) 175,000 RSUs, which will be settled into Common Stock upon a \"Change In Control\" of the Issuer, as defined in the Reporting Person's Employment Agreement, subject to the Reporting Person's continued service as of the applicable vesting date; and"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"(continued from footnote 5) (d) 31,363 shares of Common Stock owned by the Reporting Person."}],"balance_after":381363,"source":{"system":"sec-edgar","filing":"0001104659-24-128223","document":"tm2431024-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924128223/tm2431024-1_4seq1.xml","form_type":"4"}},{"id":1332717,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":37790,"kind":"person","name":"MARIANI PETER J","position":1,"cik":"0001222357","reported_name":"MARIANI PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-12-13T13:00:13.000Z","date":"2024-12-11","kind":"purchase","planned":false,"acquired":true,"shares":11363,"price":0.8891,"value":10102.8433,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects open market purchases made by the Reporting Person. The price reported in Column 4 is the weighted average price of purchases made in multiple transactions at prices ranging from $0.8289 to $0.92. The Reporting Person undertakes to provide full information regarding the number of shares purchased at each separate price within the range set forth herein upon request."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects open market purchases made by the Reporting Person. The price reported in Column 4 is the weighted average price of purchases made in multiple transactions at prices ranging from $0.8289 to $0.92. The Reporting Person undertakes to provide full information regarding the number of shares purchased at each separate price within the range set forth herein upon request."}],"balance_after":361363,"source":{"system":"sec-edgar","filing":"0001104659-24-128223","document":"tm2431024-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924128223/tm2431024-1_4seq1.xml","form_type":"4"}},{"id":1389504,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76773,"kind":"person","name":"Deliargyris Efthymios","position":1,"cik":"0001751617","reported_name":"Deliargyris Efthymios","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-09T01:00:46.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These stock options were granted pursuant to the Plan. The shares underlying these stock options will vest immediately upon the Company's achievement of Health Canada clearance or approval of DrugSorb-ATR , subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These stock options were granted pursuant to the Plan. The shares underlying these stock options will vest immediately upon the Company's achievement of Health Canada clearance or approval of DrugSorb-ATR , subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date."}],"balance_after":50000,"derivative":{"exercise_price":1.19,"expiration_date":"2034-10-04","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-24-107142","document":"tm2425809-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924107142/tm2425809-2_4seq1.xml","form_type":"4"}},{"id":1389503,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76773,"kind":"person","name":"Deliargyris Efthymios","position":1,"cik":"0001751617","reported_name":"Deliargyris Efthymios","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-09T01:00:46.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"). The shares underlying these stock options will vest immediately upon the Company's achievement of U.S. Food and Drug Administration clearance or approval of DrugSorb-ATR, subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"). The shares underlying these stock options will vest immediately upon the Company's achievement of U.S. Food and Drug Administration clearance or approval of DrugSorb-ATR, subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date."}],"balance_after":100000,"derivative":{"exercise_price":1.19,"expiration_date":"2034-10-04","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-24-107142","document":"tm2425809-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924107142/tm2425809-2_4seq1.xml","form_type":"4"}},{"id":1389506,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76776,"kind":"person","name":"Capponi Vincent","position":1,"cik":"0001368151","reported_name":"Capponi Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-09T01:00:14.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These stock options were granted pursuant to the Plan. The shares underlying these stock options will vest immediately upon the Company's achievement of Health Canada clearance or approval of DrugSorb-ATR before, subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These stock options were granted pursuant to the Plan. The shares underlying these stock options will vest immediately upon the Company's achievement of Health Canada clearance or approval of DrugSorb-ATR before, subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date."}],"balance_after":50000,"derivative":{"exercise_price":1.19,"expiration_date":"2034-10-04","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-24-107141","document":"tm2425809-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924107141/tm2425809-1_4seq1.xml","form_type":"4"}},{"id":1389505,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76776,"kind":"person","name":"Capponi Vincent","position":1,"cik":"0001368151","reported_name":"Capponi Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-09T01:00:14.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"). The shares underlying these stock options will vest immediately upon the Company's achievement of U.S. Food and Drug Administration clearance or approval of DrugSorb-ATR, subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"). The shares underlying these stock options will vest immediately upon the Company's achievement of U.S. Food and Drug Administration clearance or approval of DrugSorb-ATR, subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date."}],"balance_after":100000,"derivative":{"exercise_price":1.19,"expiration_date":"2034-10-04","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-24-107141","document":"tm2425809-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924107141/tm2425809-1_4seq1.xml","form_type":"4"}},{"id":1431630,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":37790,"kind":"person","name":"MARIANI PETER J","position":1,"cik":"0001222357","reported_name":"MARIANI PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-16T22:58:42.000Z","date":"2024-08-14","kind":"grant","planned":false,"acquired":true,"shares":215000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these stock options will vest only upon the achievement of certain milestones pursuant to the terms of the Employment Agreement, subject to the reporting person's continued service as of the applicable vesting date."}],"balance_after":215000,"derivative":{"exercise_price":0.9,"expiration_date":"2034-08-14","underlying":"Common Stock","underlying_shares":215000},"source":{"system":"sec-edgar","filing":"0001104659-24-090596","document":"tm2421901-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924090596/tm2421901-4_4seq1.xml","form_type":"4"}},{"id":1431629,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":37790,"kind":"person","name":"MARIANI PETER J","position":1,"cik":"0001222357","reported_name":"MARIANI PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-16T22:58:42.000Z","date":"2024-08-14","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these stock options vest in accordance with the following schedule: (i) 41,000 upon the six-month anniversary of the date of grant, and (ii) 13,000 on the one-year, two-year and three-year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date."}],"balance_after":80000,"derivative":{"exercise_price":0.9,"expiration_date":"2034-08-14","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001104659-24-090596","document":"tm2421901-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924090596/tm2421901-4_4seq1.xml","form_type":"4"}},{"id":1431628,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":37790,"kind":"person","name":"MARIANI PETER J","position":1,"cik":"0001222357","reported_name":"MARIANI PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-08-16T22:58:42.000Z","date":"2024-08-14","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These shares represent RSUs that will be settled into Common Stock upon a \"Change In Control\" of the Company, as defined in the reporting person's employment agreement, subject to the reporting person's continued service as of the applicable vesting date."}],"balance_after":350000,"source":{"system":"sec-edgar","filing":"0001104659-24-090596","document":"tm2421901-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924090596/tm2421901-4_4seq1.xml","form_type":"4"}},{"id":1431627,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":37790,"kind":"person","name":"MARIANI PETER J","position":1,"cik":"0001222357","reported_name":"MARIANI PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-08-16T22:58:42.000Z","date":"2024-08-14","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares represent RSUs which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting."}],"balance_after":175000,"source":{"system":"sec-edgar","filing":"0001104659-24-090596","document":"tm2421901-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924090596/tm2421901-4_4seq1.xml","form_type":"4"}},{"id":1431626,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":37790,"kind":"person","name":"MARIANI PETER J","position":1,"cik":"0001222357","reported_name":"MARIANI PETER J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-08-16T22:58:42.000Z","date":"2024-08-14","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") received as a signing bonus that will be settled into common stock, par value $0.001 per share (the \"Common Stock\") upon vesting upon the earlier of (i) a \"Change In Control\" of CytoSorbents Corporation (the \"Company\"), as defined in the reporting person's employment agreement (the \"Employment Agreement\"), or (ii) the fourth anniversary from the date of grant, subject to the reporting person's continued service as of the applicable vesting date."}],"balance_after":110000,"source":{"system":"sec-edgar","filing":"0001104659-24-090596","document":"tm2421901-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924090596/tm2421901-4_4seq1.xml","form_type":"4"}},{"id":1548013,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76778,"kind":"person","name":"Jones Edward Raymond","position":1,"cik":"0001396246","reported_name":"Jones Edward Raymond","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-05T01:47:29.000Z","date":"2024-04-02","kind":"grant","planned":false,"acquired":true,"shares":22000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":0.955,"expiration_date":"2034-04-02","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001104659-24-043796","document":"tm2411149-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924043796/tm2411149-6_4seq1.xml","form_type":"4"}},{"id":1548012,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76773,"kind":"person","name":"Deliargyris Efthymios","position":1,"cik":"0001751617","reported_name":"Deliargyris Efthymios","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-05T01:47:28.000Z","date":"2024-04-02","kind":"grant","planned":false,"acquired":true,"shares":86000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date."}],"balance_after":86000,"derivative":{"exercise_price":0.955,"expiration_date":"2034-04-02","underlying":"Common Stock","underlying_shares":86000},"source":{"system":"sec-edgar","filing":"0001104659-24-043795","document":"tm2411149-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924043795/tm2411149-3_4seq1.xml","form_type":"4"}},{"id":1548011,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76773,"kind":"person","name":"Deliargyris Efthymios","position":1,"cik":"0001751617","reported_name":"Deliargyris Efthymios","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-04-05T01:47:28.000Z","date":"2024-04-02","kind":"grant","planned":false,"acquired":true,"shares":61000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (i) the following RSUs, which vest as to two-thirds of the award on the first anniversary of the date of grant and one-third of the award on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) that will settle into shares of common stock, par value $0.001 per share (the \"Common Stock\") upon vesting: 55,000 RSUs granted on July 7, 2023 and unvested as of the date hereof;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon vesting upon a \"Change In Control\" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (a) 120,000 RSUs granted on April 9, 2020 and (b) 55,000 RSUs granted on August 10, 2022;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iii) the following RSUs that will settle into Common Stock upon vesting: (a) 20,000 RSUs granted on April 9, 2020 and unvested on the date hereof (which cliff vest on the fourth anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date) and (b) 17,334 RSUs granted on August 10, 2022 and unvested on the date hereof (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date); and"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (iv) 81,099 shares of Common Stock owned by the reporting person."}],"balance_after":409433,"source":{"system":"sec-edgar","filing":"0001104659-24-043795","document":"tm2411149-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924043795/tm2411149-3_4seq1.xml","form_type":"4"}},{"id":1548010,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76774,"kind":"person","name":"Sobel Alan D.","position":1,"cik":"0001639386","reported_name":"Sobel Alan D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-05T01:46:47.000Z","date":"2024-04-02","kind":"grant","planned":false,"acquired":true,"shares":22000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":0.955,"expiration_date":"2034-04-02","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001104659-24-043794","document":"tm2411149-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924043794/tm2411149-8_4seq1.xml","form_type":"4"}},{"id":1548009,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":92233,"kind":"person","name":"BLOCH KATHLEEN P.","position":1,"cik":"0001409212","reported_name":"BLOCH KATHLEEN P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-05T01:46:38.000Z","date":"2024-04-02","kind":"grant","planned":false,"acquired":true,"shares":87000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date."}],"balance_after":87000,"derivative":{"exercise_price":0.955,"expiration_date":"2034-04-02","underlying":"Common Stock","underlying_shares":87000},"source":{"system":"sec-edgar","filing":"0001104659-24-043793","document":"tm2411149-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924043793/tm2411149-2_4seq1.xml","form_type":"4"}},{"id":1548008,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":92233,"kind":"person","name":"BLOCH KATHLEEN P.","position":1,"cik":"0001409212","reported_name":"BLOCH KATHLEEN P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-04-05T01:46:38.000Z","date":"2024-04-02","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (i) the following RSUs, which vest as to 10,000 RSUs on the first anniversary of the date of grant, and 10,000 RSUs on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date), and will be settled into common stock, par value $0.001 per share (the \"Common Stock\"), upon vesting: 20,000 RSUs granted on September 18, 2023;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon a \"Change In Control\" of the Company, as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (a) 8,800 RSUs granted on March 15, 2018, (b) 15,700 RSUs granted on February 24, 2017, (c) 47,000 RSUs granted on June 7, 2016 and (d) 110,000 RSUs granted on April 8, 2015;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iii) the following RSUs, which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into Common Stock upon vesting: 18,500 RSUs granted on August 10, 2022; and"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (iv) 247,941 shares of Common Stock owned by the reporting person."}],"balance_after":532941,"source":{"system":"sec-edgar","filing":"0001104659-24-043793","document":"tm2411149-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924043793/tm2411149-2_4seq1.xml","form_type":"4"}},{"id":1548007,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76777,"kind":"person","name":"BATOR MICHAEL G.","position":1,"cik":"0001647591","reported_name":"BATOR MICHAEL G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-05T01:46:36.000Z","date":"2024-04-02","kind":"grant","planned":false,"acquired":true,"shares":44000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date."}],"balance_after":44000,"derivative":{"exercise_price":0.955,"expiration_date":"2034-04-02","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001104659-24-043792","document":"tm2411149-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924043792/tm2411149-5_4seq1.xml","form_type":"4"}},{"id":1548006,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76776,"kind":"person","name":"Capponi Vincent","position":1,"cik":"0001368151","reported_name":"Capponi Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-05T01:45:42.000Z","date":"2024-04-02","kind":"grant","planned":false,"acquired":true,"shares":101000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date."}],"balance_after":101000,"derivative":{"exercise_price":0.955,"expiration_date":"2034-04-02","underlying":"Common Stock","underlying_shares":101000},"source":{"system":"sec-edgar","filing":"0001104659-24-043790","document":"tm2411149-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924043790/tm2411149-4_4seq1.xml","form_type":"4"}},{"id":1548005,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76776,"kind":"person","name":"Capponi Vincent","position":1,"cik":"0001368151","reported_name":"Capponi Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2024-04-05T01:45:42.000Z","date":"2024-04-02","kind":"grant","planned":false,"acquired":true,"shares":81000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (i) the following RSUs, which vest as to two-thirds of the award on the first year anniversary of the date of grant and one-third of the award on the second year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of common stock, par value $0.001 per share (the \"Common Stock\"), of the Company upon vesting: 73,000 RSUs granted on July 7, 2023 and unvested as of the date hereof;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon vesting upon a \"Change In Control\" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (a) 10,100 RSUs granted on March 15, 2018, (b) 17,900 RSUs granted on February 24, 2017, (c) 54,000 RSUs granted on June 7, 2016 and (d) 125,000 RSUs granted on April 8, 2015;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: 23,000 RSUs granted on August 10, 2022 and unvested as of the date hereof; and"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (iv) 281,134 shares of Common Stock owned by the reporting person."}],"balance_after":665134,"source":{"system":"sec-edgar","filing":"0001104659-24-043790","document":"tm2411149-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924043790/tm2411149-4_4seq1.xml","form_type":"4"}},{"id":1548004,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76775,"kind":"person","name":"Kim Jiny","position":1,"cik":"0001920967","reported_name":"Kim Jiny","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-05T01:45:31.000Z","date":"2024-04-02","kind":"grant","planned":false,"acquired":true,"shares":22000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":0.955,"expiration_date":"2034-04-02","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001104659-24-043789","document":"tm2411149-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924043789/tm2411149-7_4seq1.xml","form_type":"4"}},{"id":1548003,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":38283,"kind":"person","name":"Chan Phillip P.","position":1,"cik":"0001442786","reported_name":"Chan Phillip P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-05T01:45:24.000Z","date":"2024-04-02","kind":"grant","planned":false,"acquired":true,"shares":124000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date."}],"balance_after":124000,"derivative":{"exercise_price":0.955,"expiration_date":"2034-04-02","underlying":"Common Stock","underlying_shares":124000},"source":{"system":"sec-edgar","filing":"0001104659-24-043788","document":"tm2411149-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924043788/tm2411149-1_4seq1.xml","form_type":"4"}},{"id":1548002,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":38283,"kind":"person","name":"Chan Phillip P.","position":1,"cik":"0001442786","reported_name":"Chan Phillip P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-04-05T01:45:24.000Z","date":"2024-04-02","kind":"grant","planned":false,"acquired":true,"shares":96000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (i) the following RSUs, which vest as to two-thirds of the award on the first year anniversary of the date of grant and one-third of the award on the second year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will settle into shares of common stock, par value $0.001 per share (the \"Common Stock\"), of the Company upon vesting: 87,000 RSUs granted on July 7, 2023 and unvested as of the date hereof;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (ii) the following RSUs that will be settled into shares of Common Stock upon vesting upon a \"Change In Control\" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first year anniversary of the date of grant, and the second year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of Common Stock upon vesting: 26,334 RSUs granted on August 10, 2022 and unvested as of the date hereof; and"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (iv) 739,370 shares of Common Stock owned by the reporting person."}],"balance_after":1164704,"source":{"system":"sec-edgar","filing":"0001104659-24-043788","document":"tm2411149-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924043788/tm2411149-1_4seq1.xml","form_type":"4"}},{"id":1554125,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76773,"kind":"person","name":"Deliargyris Efthymios","position":1,"cik":"0001751617","reported_name":"Deliargyris Efthymios","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-03T01:32:49.000Z","date":"2024-03-29","kind":"grant","planned":false,"acquired":true,"shares":47088,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person participated in a voluntary salary reduction for the period from April 1, 2024, to December 31, 2024, and these stock options were granted in connection with the salary reduction. These stock options were issued pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest fully on January 31, 2025, except as set forth on the corresponding non-qualified stock option agreement and subject to the reporting person's continued service as of the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person participated in a voluntary salary reduction for the period from April 1, 2024, to December 31, 2024, and these stock options were granted in connection with the salary reduction. These stock options were issued pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest fully on January 31, 2025, except as set forth on the corresponding non-qualified stock option agreement and subject to the reporting person's continued service as of the applicable vesting date."}],"balance_after":47088,"derivative":{"exercise_price":0.95,"expiration_date":"2034-03-29","underlying":"Common Stock","underlying_shares":47088},"source":{"system":"sec-edgar","filing":"0001104659-24-042776","document":"tm2410664-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924042776/tm2410664-4_4seq1.xml","form_type":"4"}},{"id":1554124,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76776,"kind":"person","name":"Capponi Vincent","position":1,"cik":"0001368151","reported_name":"Capponi Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-03T01:32:07.000Z","date":"2024-03-29","kind":"grant","planned":false,"acquired":true,"shares":48923,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person participated in a voluntary salary reduction for the period from April 1, 2024, to December 31, 2024, and these stock options were granted in connection with the salary reduction. These stock options were issued pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest fully on January 31, 2025, except as set forth on the corresponding non-qualified stock option agreement and subject to the reporting person's continued service as of the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person participated in a voluntary salary reduction for the period from April 1, 2024, to December 31, 2024, and these stock options were granted in connection with the salary reduction. These stock options were issued pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest fully on January 31, 2025, except as set forth on the corresponding non-qualified stock option agreement and subject to the reporting person's continued service as of the applicable vesting date."}],"balance_after":48923,"derivative":{"exercise_price":0.95,"expiration_date":"2034-03-29","underlying":"Common Stock","underlying_shares":129998},"source":{"system":"sec-edgar","filing":"0001104659-24-042775","document":"tm2410664-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924042775/tm2410664-3_4seq1.xml","form_type":"4"}},{"id":1554122,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":92233,"kind":"person","name":"BLOCH KATHLEEN P.","position":1,"cik":"0001409212","reported_name":"BLOCH KATHLEEN P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-03T01:31:14.000Z","date":"2024-03-29","kind":"grant","planned":false,"acquired":true,"shares":49038,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person participated in a voluntary salary reduction for the period from April 1, 2024, to December 31, 2024, and these stock\noptions were granted in connection with the salary reduction. These stock options were issued pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest fully on January 31, 2025, except as set forth on the corresponding non-qualified stock option agreement and subject to the reporting person's continued service as of the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person participated in a voluntary salary reduction for the period from April 1, 2024, to December 31, 2024, and these stock\noptions were granted in connection with the salary reduction. These stock options were issued pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest fully on January 31, 2025, except as set forth on the corresponding non-qualified stock option agreement and subject to the reporting person's continued service as of the applicable vesting date."}],"balance_after":49038,"derivative":{"exercise_price":0.95,"expiration_date":"2034-03-29","underlying":"Common Stock","underlying_shares":49038},"source":{"system":"sec-edgar","filing":"0001104659-24-042774","document":"tm2410664-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924042774/tm2410664-2_4seq1.xml","form_type":"4"}},{"id":1554123,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":38283,"kind":"person","name":"Chan Phillip P.","position":1,"cik":"0001442786","reported_name":"Chan Phillip P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-03T01:30:40.000Z","date":"2024-03-29","kind":"grant","planned":false,"acquired":true,"shares":129998,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person participated in a voluntary salary reduction for the period from April 1, 2024, to December 31, 2024, and these stock options were granted in connection with the salary reduction. These stock options were issued pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest fully on January 31, 2025, except as set forth on the corresponding non-qualified stock option agreement and subject to the reporting person's continued service as of the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person participated in a voluntary salary reduction for the period from April 1, 2024, to December 31, 2024, and these stock options were granted in connection with the salary reduction. These stock options were issued pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest fully on January 31, 2025, except as set forth on the corresponding non-qualified stock option agreement and subject to the reporting person's continued service as of the applicable vesting date."}],"balance_after":129998,"derivative":{"exercise_price":0.95,"expiration_date":"2034-03-29","underlying":"Common Stock","underlying_shares":129998},"source":{"system":"sec-edgar","filing":"0001104659-24-042772","document":"tm2410664-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924042772/tm2410664-1_4seq1.xml","form_type":"4"}},{"id":1709636,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76774,"kind":"person","name":"Sobel Alan D.","position":1,"cik":"0001639386","reported_name":"Sobel Alan D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2023-12-15T21:35:14.000Z","date":"2023-12-13","kind":"purchase","planned":false,"acquired":true,"shares":7894,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant."}],"balance_after":7894,"derivative":{"exercise_price":2,"exercise_date":"2023-12-13","expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":7894},"source":{"system":"sec-edgar","filing":"0001104659-23-126432","document":"tm2332958-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923126432/tm2332958-5_4seq1.xml","form_type":"4"}},{"id":1709635,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76774,"kind":"person","name":"Sobel Alan D.","position":1,"cik":"0001639386","reported_name":"Sobel Alan D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-15T21:35:14.000Z","date":"2023-12-13","kind":"purchase","planned":false,"acquired":true,"shares":22557,"price":1.33,"value":30000.81,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (i) the following restricted stock units (\"RSUs\") that will be settled into Common Stock upon vesting upon a \"Change in Control\" of the Company, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (a) 3,300 RSUs granted on March 15, 2018, (b) 6,000 RSUs granted on February 24, 2017, (c) 5,000 RSUs granted on June 7, 2016, and (d) 55,000 RSUs granted on April 8, 2015 and (ii) 32,557 shares of Common Stock owned directly by the reporting person."}],"balance_after":101857,"source":{"system":"sec-edgar","filing":"0001104659-23-126432","document":"tm2332958-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923126432/tm2332958-5_4seq1.xml","form_type":"4"}},{"id":1709634,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76773,"kind":"person","name":"Deliargyris Efthymios","position":1,"cik":"0001751617","reported_name":"Deliargyris Efthymios","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2023-12-15T21:34:16.000Z","date":"2023-12-13","kind":"purchase","planned":false,"acquired":true,"shares":7894,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant."}],"balance_after":7894,"derivative":{"exercise_price":2,"exercise_date":"2023-12-13","expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":7894},"source":{"system":"sec-edgar","filing":"0001104659-23-126431","document":"tm2332958-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923126431/tm2332958-4_4seq1.xml","form_type":"4"}},{"id":1709633,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76773,"kind":"person","name":"Deliargyris Efthymios","position":1,"cik":"0001751617","reported_name":"Deliargyris Efthymios","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-12-15T21:34:16.000Z","date":"2023-12-13","kind":"purchase","planned":false,"acquired":true,"shares":22557,"price":1.33,"value":30000.81,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (i) the following restricted stock units (\"RSUs\") (which vest as to two-thirds of the award on the first anniversary of the date of grant and one-third of the award on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) that will settle into shares of Common Stock upon vesting: 55,000 RSUs granted on July 7, 2023 and unvested as of the date hereof;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon vesting upon a \"Change In Control\" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (a) 120,000 RSUs granted on April 9, 2020 and (b) 55,000 RSUs granted on August 10, 2022;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iii) the following RSUs that will settle into Common Stock upon vesting: (a) 20,000 RSUs granted on April 9, 2020 and unvested on the date hereof (which cliff vest on the fourth anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date) and (b) 17,334 RSUs granted on August 10, 2022 and unvested on the date hereof (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date); and"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (iv) 81,099 shares of Common Stock owned by the reporting person."}],"balance_after":348433,"source":{"system":"sec-edgar","filing":"0001104659-23-126431","document":"tm2332958-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923126431/tm2332958-4_4seq1.xml","form_type":"4"}},{"id":1709632,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76776,"kind":"person","name":"Capponi Vincent","position":1,"cik":"0001368151","reported_name":"Capponi Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2023-12-15T21:34:14.000Z","date":"2023-12-13","kind":"purchase","planned":false,"acquired":true,"shares":6578,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant."}],"balance_after":6578,"derivative":{"exercise_price":2,"exercise_date":"2023-12-13","expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":6578},"source":{"system":"sec-edgar","filing":"0001104659-23-126430","document":"tm2332958-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923126430/tm2332958-6_4seq1.xml","form_type":"4"}},{"id":1709631,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76776,"kind":"person","name":"Capponi Vincent","position":1,"cik":"0001368151","reported_name":"Capponi Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2023-12-15T21:34:14.000Z","date":"2023-12-13","kind":"purchase","planned":false,"acquired":true,"shares":18797,"price":1.33,"value":25000.01,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (i) the following restricted stock units (\"RSUs\") (which vest as to two-thirds of the award on the first anniversary of the date of grant and one-third of the award on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of Common Stock upon vesting: 73,000 RSUs granted on July 7, 2023 and unvested as of the date hereof;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon vesting upon a \"Change In Control\" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (a) 10,100 RSUs granted on March 15, 2018, (b) 17,900 RSUs granted on February 24, 2017, (c) 54,000 RSUs granted on June 7, 2016 and (d) 125,000 RSUs granted on April 8, 2015;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: 23,000 RSUs granted on August 10, 2022 and unvested as of the date hereof; and"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (iv) 281,134 shares of Common Stock owned by the reporting person."}],"balance_after":584134,"source":{"system":"sec-edgar","filing":"0001104659-23-126430","document":"tm2332958-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923126430/tm2332958-6_4seq1.xml","form_type":"4"}},{"id":1709630,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76777,"kind":"person","name":"BATOR MICHAEL G.","position":1,"cik":"0001647591","reported_name":"BATOR MICHAEL G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2023-12-15T21:33:21.000Z","date":"2023-12-13","kind":"purchase","planned":false,"acquired":true,"shares":13157,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant."}],"balance_after":13157,"derivative":{"exercise_price":2,"exercise_date":"2023-12-13","expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":13157},"source":{"system":"sec-edgar","filing":"0001104659-23-126429","document":"tm2332958-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923126429/tm2332958-3_4seq1.xml","form_type":"4"}},{"id":1709629,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76777,"kind":"person","name":"BATOR MICHAEL G.","position":1,"cik":"0001647591","reported_name":"BATOR MICHAEL G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-15T21:33:21.000Z","date":"2023-12-13","kind":"purchase","planned":false,"acquired":true,"shares":37594,"price":1.33,"value":50000.02,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (a) the following restricted stock units (\"RSUs\") which will vest upon a \"Change of Control\" of the Company, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\"): (i) 3,300 RSUs granted on March 15, 2018, (ii) 6,000 RSUs granted on February 24, 2017, and (iii) 60,000 RSUs granted on June 7, 2016, and (b) 56,094 shares of Common Stock owned by the reporting person."}],"balance_after":125394,"source":{"system":"sec-edgar","filing":"0001104659-23-126429","document":"tm2332958-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923126429/tm2332958-3_4seq1.xml","form_type":"4"}},{"id":1709628,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76778,"kind":"person","name":"Jones Edward Raymond","position":1,"cik":"0001396246","reported_name":"Jones Edward Raymond","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2023-12-15T21:32:55.000Z","date":"2023-12-13","kind":"purchase","planned":false,"acquired":true,"shares":2631,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant."}],"balance_after":2631,"derivative":{"exercise_price":2,"exercise_date":"2023-12-13","expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":2631},"source":{"system":"sec-edgar","filing":"0001104659-23-126428","document":"tm2332958-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923126428/tm2332958-7_4seq1.xml","form_type":"4"}},{"id":1709627,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76778,"kind":"person","name":"Jones Edward Raymond","position":1,"cik":"0001396246","reported_name":"Jones Edward Raymond","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-15T21:32:55.000Z","date":"2023-12-13","kind":"purchase","planned":false,"acquired":true,"shares":7519,"price":1.33,"value":10000.27,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (i) the following Restricted Stock Units (\"RSUs\") that will be settled into Common Stock vesting upon a \"Change In Control\" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 55,000 RSUs granted on April 8, 2015, (b) 5,000 RSUs granted on June 7, 2016, (c) 6,000 RSUs granted on February 24, 2017 and (d) 3,300 RSUs granted on March 15, 2018; and (ii) 19,534 shares of Common Stock owned by the reporting person."}],"balance_after":88834,"source":{"system":"sec-edgar","filing":"0001104659-23-126428","document":"tm2332958-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923126428/tm2332958-7_4seq1.xml","form_type":"4"}},{"id":1709624,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":92233,"kind":"person","name":"BLOCH KATHLEEN P.","position":1,"cik":"0001409212","reported_name":"BLOCH KATHLEEN P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2023-12-15T21:32:14.000Z","date":"2023-12-13","kind":"purchase","planned":false,"acquired":true,"shares":13157,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant"}],"balance_after":13157,"derivative":{"exercise_price":2,"exercise_date":"2023-12-13","expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":13157},"source":{"system":"sec-edgar","filing":"0001104659-23-126427","document":"tm2332958-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923126427/tm2332958-2_4seq1.xml","form_type":"4"}},{"id":1709623,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":92233,"kind":"person","name":"BLOCH KATHLEEN P.","position":1,"cik":"0001409212","reported_name":"BLOCH KATHLEEN P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-12-15T21:32:14.000Z","date":"2023-12-13","kind":"purchase","planned":false,"acquired":true,"shares":37594,"price":1.33,"value":50000.02,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (i) the following restricted stock units (\"RSUs\") (which vest as to 10,000 RSUs on the first anniversary of the date of grant, and 10,000 RSUs on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date), and will be settled into Common Stock upon vesting: 20,000 RSUs granted on September 18, 2023;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon a \"Change In Control\" of the Company, as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 8,800 RSUs granted on March 15, 2018, (b) 15,700 RSUs granted on February 24, 2017, (c) 47,000 RSUs granted on June 7, 2016 and (d) 110,000 RSUs granted on April 8, 2015;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"(continued from footnote 3) (iii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date), and will be settled into Common Stock upon vesting: 18,500 RSUs granted on August 10, 2022; and"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"(continued from footnote 4) (iv) 247,941 shares of Common Stock owned by the reporting person."}],"balance_after":467941,"source":{"system":"sec-edgar","filing":"0001104659-23-126427","document":"tm2332958-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923126427/tm2332958-2_4seq1.xml","form_type":"4"}},{"id":1709626,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76775,"kind":"person","name":"Kim Jiny","position":1,"cik":"0001920967","reported_name":"Kim Jiny","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2023-12-15T21:31:42.000Z","date":"2023-12-13","kind":"purchase","planned":false,"acquired":true,"shares":2631,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant."}],"balance_after":2631,"derivative":{"exercise_price":2,"exercise_date":"2023-12-13","expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":2631},"source":{"system":"sec-edgar","filing":"0001104659-23-126424","document":"tm2332958-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923126424/tm2332958-8_4seq1.xml","form_type":"4"}},{"id":1709625,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":76775,"kind":"person","name":"Kim Jiny","position":1,"cik":"0001920967","reported_name":"Kim Jiny","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-15T21:31:42.000Z","date":"2023-12-13","kind":"purchase","planned":false,"acquired":true,"shares":7519,"price":1.33,"value":10000.27,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (a) 69,300 restricted stock units (\"RSUs\") granted on April 1, 2022 that will be settled into shares of Common Stock upon vesting upon a \"Change In Control\" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the \"Plan\") and (b) 8,519 shares of Common Stock owned by the reporting person."}],"balance_after":77819,"source":{"system":"sec-edgar","filing":"0001104659-23-126424","document":"tm2332958-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923126424/tm2332958-8_4seq1.xml","form_type":"4"}},{"id":1709622,"issuer":{"id":7625,"kind":"organization","name":"Cytosorbents Corp","symbol":"CTSO"},"owners":[{"id":38283,"kind":"person","name":"Chan Phillip P.","position":1,"cik":"0001442786","reported_name":"Chan Phillip P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2023-12-15T21:30:43.000Z","date":"2023-12-13","kind":"purchase","planned":false,"acquired":true,"shares":26315,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed\non December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased\ntogether with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common\nStock and accompanying warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the \"Company\"), which closed\non December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the \"Common Stock\") of the Company was purchased\ntogether with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common\nStock and accompanying warrant."}],"balance_after":26315,"derivative":{"exercise_price":2,"exercise_date":"2023-12-13","expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":26315},"source":{"system":"sec-edgar","filing":"0001104659-23-126421","document":"tm2332958-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465923126421/tm2332958-1_4seq1.xml","form_type":"4"}}],"next_cursor":"2023-12-15T21:30:43.000000Z,1709622"}